{"protocolSection":{"identificationModule":{"nctId":"NCT03883113","orgStudyIdInfo":{"id":"FLU010"},"organization":{"fullName":"Barinthus Biotherapeutics","class":"INDUSTRY"},"briefTitle":"Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model","officialTitle":"Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model"},"statusModule":{"statusVerifiedDate":"2021-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-06-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-12-16","type":"ACTUAL"},"completionDateStruct":{"date":"2020-04-17","type":"ACTUAL"},"studyFirstSubmitDate":"2019-02-21","studyFirstSubmitQcDate":"2019-03-18","studyFirstPostDateStruct":{"date":"2019-03-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-12-04","resultsFirstSubmitQcDate":"2021-03-17","resultsFirstPostDateStruct":{"date":"2021-03-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-03-17","lastUpdatePostDateStruct":{"date":"2021-03-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Barinthus Biotherapeutics","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.","detailedDescription":"The study consists of an outpatient vaccination phase (155 participants), and at least 2 months later an inpatient challenge phase (134 participants). Participants are randomized 93:62 to receive either MVA-NP+M1 or Placebo. Up to 20 participants will be challenged over several 3-week blocks, and the remainder at the final 3-week block for a total of 80 MVA-NP+M1 and 54 Placebo recipients challenged."},"conditionsModule":{"conditions":["Influenza"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":145,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MVA-NP+M1 & H3N2 Challenge Virus","type":"EXPERIMENTAL","description":"Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)","interventionNames":["Biological: MVA-NP+M1","Biological: H3N2 (A/Belgium/2417/2015)"]},{"label":"Saline Placebo & H3N2 Challenge Virus","type":"PLACEBO_COMPARATOR","description":"Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)","interventionNames":["Biological: Saline","Biological: H3N2 (A/Belgium/2417/2015)"]}],"interventions":[{"type":"BIOLOGICAL","name":"MVA-NP+M1","description":"Trial Vaccine","armGroupLabels":["MVA-NP+M1 & H3N2 Challenge Virus"]},{"type":"BIOLOGICAL","name":"Saline","description":"Sodium Chloride Placebo","armGroupLabels":["Saline Placebo & H3N2 Challenge Virus"]},{"type":"BIOLOGICAL","name":"H3N2 (A/Belgium/2417/2015)","description":"Challenge Agent","armGroupLabels":["MVA-NP+M1 & H3N2 Challenge Virus","Saline Placebo & H3N2 Challenge Virus"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR","description":"Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.","timeFrame":"Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart."}],"secondaryOutcomes":[{"measure":"Number and Percentage of Virologically Confirmed Influenza-Like Illness","description":"Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.","timeFrame":"9 days from day 2 to day 10"},{"measure":"Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)","description":"The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days","timeFrame":"9 days from day 2 to day 10"},{"measure":"Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)","description":"The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days","timeFrame":"9 days from day 2 to day 10"},{"measure":"Time to Start of Viral Shedding (qPCR) From Virus Inoculation","description":"The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60\\*60)","timeFrame":"9 days from day 2 to day 10"},{"measure":"Time to Start of Viral Shedding (qCulture) From Virus Inoculation","description":"Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60\\*60)","timeFrame":"9 days from day 2 to day 10"},{"measure":"Peak Viral Shedding (qPCR) After the Virus Inoculation","description":"This is measured by the highest viral load concentration by qPCR","timeFrame":"9 days from Day 2 to Day 10"},{"measure":"Peak Viral Shedding (qCulture) After Virus Inoculation","description":"This is measured by the highest viral load concentration by qCulture.","timeFrame":"9 days from day 2 to day 10"},{"measure":"Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation","description":"This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60\\*60)","timeFrame":"9 days from day 2 to day 10"},{"measure":"Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation","description":"This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60\\*60)","timeFrame":"9 days from day 2 to day 10"},{"measure":"Duration of Viral Shedding (qPCR) After the Virus Inoculation","description":"It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60\\*60)","timeFrame":"9 days from day2 to day10"},{"measure":"Duration of Viral Shedding (qCulture) After the Virus Inoculation","description":"It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60\\*60)","timeFrame":"9 days from day 2 to day 10"},{"measure":"Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)","description":"Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score.\n\nSymptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC).\n\nSSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM).\n\nParticipants rated the severity of symptoms, higher scores indicating a more severe symptom.\n\nThe scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work \"today\" (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3.\n\nThe SSC AUC \\[0-11 days\\] was derived based on the Overall SSC score against time (\\*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score\\*hour.","timeFrame":"11 days from Day 1 to Day 11"},{"measure":"Total Days of Fever","description":"Total days of fever for MVA-NP+M1 vs. Placebo","timeFrame":"11 days from Day 1 to Day 11"},{"measure":"Average Total Mucus Production","description":"Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo.\n\nTotal mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).","timeFrame":"11 days from Day 1 to Day 11"},{"measure":"T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence","description":"T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay.\n\nFor each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO).\n\nThe number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported.\n\nThe endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.","timeFrame":"3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)"},{"measure":"Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms","description":"Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries","timeFrame":"7 days following vaccination"},{"measure":"Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms","description":"Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring","timeFrame":"17 days following vaccination"}],"otherOutcomes":[{"measure":"Severity of Individual Symptoms for MVA-NP+M1 vs. Placebo","description":"Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo","timeFrame":"11 days"},{"measure":"Total Symptom Score Time to Start, Time to Peak and Duration","description":"Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate\n\nInfluenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).","timeFrame":"11 days"},{"measure":"Correlation of T Cell Phenotypes With Illness Outcomes","description":"Correlation of antigen specific T Cell phenotypes with illness outcomes","timeFrame":"3 months"},{"measure":"Vaccination Effect on Antibody Responses by ELISpot and ICS Assays","description":"Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy males and females aged ≥18 and ≤55 years of age at the point of enrolment.\n* Non-smokers or those who stopped smoking ≥ 3 months prior to screening 1 visit.\n* Willingness to remain in isolation for the duration of the study.\n* A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:\n\n  1. Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).\n  2. Of childbearing potential but has been and agrees to continue practicing highly effective contraception or abstinence (if this is the preferred and usual lifestyle of the participant) from 6 months prior to vaccination to 6 months after administration of the influenza challenge virus. Highly effective methods of contraception include 1 or more of the following:\n\n  i. male partner who is sterile (vasectomised) prior to the female participants entry into the study and is the sole sexual partner for the female participant; ii. hormonal (oral, intravaginal, transdermal, implantable or injectable); iii. an intrauterine hormone-releasing system (IUS); iv. an intrauterine device (IUD) with a documented failure rate of \\< 1%; v. bilateral tubal occlusion.\n* Pre-challenge serum microneutralization test (MNT) against A/Belgium/4217/2015 (H3N2) challenge strain \\< 20.\n\nExclusion Criteria:\n\n* BMI \\< 19 and \\> 32.\n* Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness including a history of chronic respiratory illness.\n* History of seasonal hay fever or a clinically significant seasonal allergic rhinitis (SAR), including the use of symptomatic prescription only medication and non-prescription medication.\n* History or evidence of autoimmune disease or known immunodeficiency of any cause - with the exception of atopic dermatitis/eczema and atopic rhinitis.\n* Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine.\n* History of lung disease (Asthma, COPD).\n* Current smokers or those who stopped smoking \\< 3months prior to screening 1 visit.\n* Positive diagnostic tests for HIV, Hepatitis B or Hepatitis C indicating active infection.\n* Evidence of drug abuse or a positive urine drug screen or alcohol breath test.\n* Chronic use of any medication or other product (prescription or over-the-counter), for symptoms of rhinitis or nasal congestion or for any chronic nasopharyngeal complaint, or chronic use of any intranasal medication for any indication that has not ceased within 30 days prior to screening 1.\n* Receipt of any investigational drug within 3 months prior to vaccination, or prior participation in a clinical trial of any influenza vaccine, or any investigational vaccine or experimental influenza viral challenge delivered directly to the respiratory tract within 1 year prior to challenge.\n* Receipt of the 2018/2019 seasonal flu vaccine.\n* Receipt of any live vaccines within the 4 weeks prior to vaccination.\n* Any laboratory test which is abnormal and which is deemed by the Investigator(s) to be clinically significant.\n* Receipt of any systemic chemotherapy agent at any time.\n* Physician reported influenza or a syndrome consistent with influenza (as judged by the investigator) in the previous 6 months.\n* Known allergy to treatments for influenza (including but not limited to oseltamivir).\n* History of frequent epistaxis (nose bleeds).\n* Any nasal or sinus surgery within 6 months of Viral Challenge or any significant abnormality, either of which results in alteration of the anatomy of the nose or nasopharynx (including significant nasal polyps).\n* Volunteers with household contacts who are at risk for serious or severe complications of influenza disease including, but not limited to: persons ≥ 65 years; presence of significant chronic cardiopulmonary, metabolic, renal, or neurological conditions; immunosuppression due to any condition or therapies; BMI \\>40.\n* Participants that are an employee or family member of the Investigator or study site personnel may not be enrolled.\n* Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.\n\nEXCLUSION (CHALLENGE PERIOD ONLY)\n\n* Abnormal spirometry assessed to be clinically significant.\n* Known close contact with anyone known to have influenza in the past 7 days at the time of quarantine.\n* Influenza-like illness (ILI) symptoms as assessed at the admission to clinic on Day -2 prior to challenge.\n* Presence of fever, defined as participant presenting with a temperature reading of \\> 38.0°C on admission to quarantine.\n* Qualitative Polymerase chain reaction (PCR) results positive for viral infection. However, participants may be included into later challenge cohort.\n* Acute use of any medication or other product, prescription or over-the-counter, for symptoms of rhinitis or nasal congestion within 7 days prior to challenge. This includes any oral corticosteroid or beta agonist containing nasal spray.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Robin Rogiers, MD","affiliation":"SGS S.A.","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"SGS Life Sciences, Clinical Pharmacology Unit (CPU)","city":"Antwerp","zip":"2060","country":"Belgium","geoPoint":{"lat":51.22047,"lon":4.40026}}]},"referencesModule":{"references":[{"pmid":"38729196","type":"DERIVED","citation":"Evans TG, Castellino F, Kowalik Dobczyk M, Tucker G, Walley AM, Van Leuven K, Klein J, Rutkowski K, Ellis C, Eagling-Vose E, Treanor J, van Baalen C, Filkov E, Laurent C, Thacker J, Asher J, Donabedian A. Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study. Lancet Microbe. 2024 Jul;5(7):645-654. doi: 10.1016/S2666-5247(24)00024-7. Epub 2024 May 7."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eight-hundred and nineteen (819) subjects were screened. One hundred and forty-five (145) subjects were actually enrolled and vaccinated. The study consisted of an outpatient vaccination phase and at least 6 weeks later an inpatient challenge phase.","recruitmentDetails":"The study was conducted at the SGS Clinical Pharmacology Unit in Antwerp, Belgium.","groups":[{"id":"FG000","title":"MVA-NP+M1 & H3N2 Challenge Virus","description":"Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)\n\nMVA-NP+M1: Trial Vaccine\n\nH3N2 (A/Belgium/2417/2015): Challenge Agent"},{"id":"FG001","title":"Saline Placebo & H3N2 Challenge Virus","description":"Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)\n\nSaline: Sodium Chloride Placebo\n\nH3N2 (A/Belgium/2417/2015): Challenge Agent"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"12"}]}],"dropWithdraws":[{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Challenge Criteria Not Met / Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"MVA-NP+M1 & H3N2 Challenge Virus","description":"Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)\n\nMVA-NP+M1: Trial Vaccine\n\nH3N2 (A/Belgium/2417/2015): Challenge Agent"},{"id":"BG001","title":"Saline Placebo & H3N2 Challenge Virus","description":"Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)\n\nSaline: Sodium Chloride Placebo\n\nH3N2 (A/Belgium/2417/2015): Challenge Agent"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"145"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"145"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"43.00","lowerLimit":"18.5","upperLimit":"55.9"},{"groupId":"BG001","value":"41.25","lowerLimit":"19.9","upperLimit":"55.7"},{"groupId":"BG002","value":"42.50","lowerLimit":"18.5","upperLimit":"55.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"78"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"67"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]}]},{"title":"Middle Eastern","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"138"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"145"}]}]}]},{"title":"Smoking Status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Ex-smoker","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"45"}]},{"title":"Non-smoker","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"100"}]}]}]},{"title":"Height","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"cm","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"172.40","lowerLimit":"153.2","upperLimit":"193.3"},{"groupId":"BG001","value":"172.30","lowerLimit":"151.8","upperLimit":"191.7"},{"groupId":"BG002","value":"172.40","lowerLimit":"151.8","upperLimit":"193.3"}]}]}]},{"title":"Weight","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72.9","lowerLimit":"53.2","upperLimit":"118.8"},{"groupId":"BG001","value":"75.15","lowerLimit":"54.6","upperLimit":"105.6"},{"groupId":"BG002","value":"73.60","lowerLimit":"53.2","upperLimit":"118.8"}]}]}]},{"title":"BMI","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24.7","lowerLimit":"19.0","upperLimit":"32"},{"groupId":"BG001","value":"25.5","lowerLimit":"19.2","upperLimit":"31.2"},{"groupId":"BG002","value":"24.90","lowerLimit":"19.0","upperLimit":"32.0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR","description":"Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.","populationDescription":"End point values","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hour*Log10 Viral Particles/ ml","timeFrame":"Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart.","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat (the actually challenged with the virus)"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat (the actually challenged with the virus)"},{"id":"OG002","title":"MVA-NP+M1 (PP)","description":"Per protocol analysis set"},{"id":"OG003","title":"Placebo (PP)","description":"Per protocol analysis set"},{"id":"OG004","title":"MVA-NP+M1 (Challenge)","description":"Safety Analysis Set (challenged participants)"},{"id":"OG005","title":"Placebo (Challenge)","description":"Safety Analysis Set (challenged participants)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"47"},{"groupId":"OG004","value":"71"},{"groupId":"OG005","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"649.7","lowerLimit":"552.7","upperLimit":"746.7"},{"groupId":"OG001","value":"726.1","lowerLimit":"604.0","upperLimit":"848.2"},{"groupId":"OG002","value":"646.5","lowerLimit":"548.3","upperLimit":"744.7"},{"groupId":"OG003","value":"726.1","lowerLimit":"604.0","upperLimit":"848.2"},{"groupId":"OG004","value":"649.7","lowerLimit":"552.7","upperLimit":"746.7"},{"groupId":"OG005","value":"726.1","lowerLimit":"604.0","upperLimit":"848.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.1711","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","pValue":"0.1654","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG004","OG005"],"nonInferiorityType":"OTHER","pValue":"0.1711","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Number and Percentage of Virologically Confirmed Influenza-Like Illness","description":"Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"title":"Virologically confirmed Influenza-like Illness","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"29"}]}]},{"title":"No Virologically Confirmed Influenza-like Illness","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"18"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The statistical analysis applies to participants with Virologically confirmed Influenza-like Illness versus participants without Virologically confirmed Influenza-like Illness","nonInferiorityType":"OTHER","pValue":"1.000","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)","description":"The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"title":"qPCR-confirmed influenza","categories":[{"measurements":[{"groupId":"OG000","value":"90.1","lowerLimit":"80.7","upperLimit":"95.9"},{"groupId":"OG001","value":"97.9","lowerLimit":"88.7","upperLimit":"99.9"}]}]},{"title":"No qPCR influenza","categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"4.1","upperLimit":"19.3"},{"groupId":"OG001","value":"2.1","lowerLimit":"0.1","upperLimit":"11.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"This statistical analysis applies to participants with qPCR confirmed Influenza versus participants with no qPCR confirmed Influenza","nonInferiorityType":"OTHER","pValue":"0.143","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)","description":"The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"title":"qCulture confirmed influenza","categories":[{"measurements":[{"groupId":"OG000","value":"77.5","lowerLimit":"66.0","upperLimit":"86.5"},{"groupId":"OG001","value":"85.1","lowerLimit":"71.7","upperLimit":"93.8"}]}]},{"title":"No qCulture-confirmed influenza","categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"13.5","upperLimit":"34.0"},{"groupId":"OG001","value":"14.9","lowerLimit":"6.2","upperLimit":"28.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"This statistical analysis applies to participants with qCulture confirmed Influenza versus participants without qCulture confirmed Influenza","nonInferiorityType":"OTHER","pValue":"0.3504","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Time to Start of Viral Shedding (qPCR) From Virus Inoculation","description":"The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60\\*60)","populationDescription":"\\[MVA-NP+M1 (ITT)\\] - subjects assessed = 71 subjects with event = 64 subjects censored = 7 \\[Placebo (ITT)\\] - subjects assessed = 47 subjects with event = 46 subjects censored = 1","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hours","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.40","lowerLimit":"24.30","upperLimit":"24.50"},{"groupId":"OG001","value":"24.30","lowerLimit":"24.20","upperLimit":"24.50"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.5558","statisticalMethod":"Log Rank"}]},{"type":"SECONDARY","title":"Time to Start of Viral Shedding (qCulture) From Virus Inoculation","description":"Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60\\*60)","populationDescription":"\\[MVA-NP+M1(ITT)\\] - Subjects assessed = 71 Subjects with event = 55 Subjects censored = 16; \\[Placebo (ITT)\\] - Subjects assessed = 47 Subjects with event = 40 Subjects censored = 7","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hours","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","lowerLimit":"35.60","upperLimit":"48.00"},{"groupId":"OG001","value":"47.6","lowerLimit":"24.70","upperLimit":"48.50"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.6534","statisticalMethod":"Log Rank"}]},{"type":"SECONDARY","title":"Peak Viral Shedding (qPCR) After the Virus Inoculation","description":"This is measured by the highest viral load concentration by qPCR","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Log10 Viral Particles/ ml","timeFrame":"9 days from Day 2 to Day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT) Successful Attack","description":"Subset of participants who received MVA-NP+M1 and with a successful attack"},{"id":"OG001","title":"Placebo (ITT) Successful Attack","description":"Subset of participants who received Placebo and with a successful attack"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.876","lowerLimit":"5.430","upperLimit":"6.322"},{"groupId":"OG001","value":"6.054","lowerLimit":"5.521","upperLimit":"6.587"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.5485","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Peak Viral Shedding (qCulture) After Virus Inoculation","description":"This is measured by the highest viral load concentration by qCulture.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Log10 Viral Particles/ ml","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT) Successful Attack","description":"Subset of participants who received MVA-NP+M1 and with a successful attack"},{"id":"OG001","title":"Placebo (ITT) Successful Attack","description":"Subset of participants who received Placebo and with a successful attack"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.073","lowerLimit":"3.683","upperLimit":"4.463"},{"groupId":"OG001","value":"4.069","lowerLimit":"3.442","upperLimit":"4.695"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.6753","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation","description":"This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60\\*60)","populationDescription":"\\[MVA-NP+M1 (ITT)\\] - Subjects assessed = 71 Subjects with event = 64 Subjects censored = 7; \\[Placebo (ITT)\\] - Subjects assessed = 47 Subjects with event = 46 Subjects censored = 1","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hours","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.20","lowerLimit":"60.00","upperLimit":"96.00"},{"groupId":"OG001","value":"107.90","lowerLimit":"72.20","upperLimit":"119.80"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.711","statisticalMethod":"Log Rank"}]},{"type":"SECONDARY","title":"Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation","description":"This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60\\*60)","populationDescription":"\\[MVA-NP+M1 (ITT)\\] - Subjects assessed = 71 Subjects with event = 55 Subjects censored = 16; \\[Placebo (ITT)\\] - Subjects assessed = 47 Subjects with event = 40 Subjects censored = 7","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hours","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.40","lowerLimit":"60.10","upperLimit":"96.30"},{"groupId":"OG001","value":"83.80","lowerLimit":"60.10","upperLimit":"96.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.4689","statisticalMethod":"Log Rank"}]},{"type":"SECONDARY","title":"Duration of Viral Shedding (qPCR) After the Virus Inoculation","description":"It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60\\*60)","populationDescription":"This endpoint is only calculated for the subset of participants with a successful attack.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hours","timeFrame":"9 days from day2 to day10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT) Successful Attack","description":"Subset of participants who received MVA-NP+M1 and with a successful attack"},{"id":"OG001","title":"Placebo (ITT) Successful Attack","description":"Subset of participants who received Placebo and with a successful attack"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.80","lowerLimit":"157.08","upperLimit":"184.52"},{"groupId":"OG001","value":"172.47","lowerLimit":"156.99","upperLimit":"187.94"}]}]}]},{"type":"SECONDARY","title":"Duration of Viral Shedding (qCulture) After the Virus Inoculation","description":"It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60\\*60)","populationDescription":"This endpoint is only calculated for the subset of participants with a successful attack","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hours","timeFrame":"9 days from day 2 to day 10","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT) Successful Attack","description":"Subset of participants who received MVA-NP+M1 and with a successful attack"},{"id":"OG001","title":"Placebo (ITT) Successful Attack","description":"Subset of participants who received Placebo and with a successful attack"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118.19","lowerLimit":"105.07","upperLimit":"131.31"},{"groupId":"OG001","value":"121.78","lowerLimit":"106.33","upperLimit":"137.23"}]}]}]},{"type":"SECONDARY","title":"Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)","description":"Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score.\n\nSymptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC).\n\nSSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM).\n\nParticipants rated the severity of symptoms, higher scores indicating a more severe symptom.\n\nThe scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work \"today\" (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3.\n\nThe SSC AUC \\[0-11 days\\] was derived based on the Overall SSC score against time (\\*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score\\*hour.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Composite symptom score on scale*hour","timeFrame":"11 days from Day 1 to Day 11","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.709","lowerLimit":"11.568","upperLimit":"21.850"},{"groupId":"OG001","value":"20.432","lowerLimit":"13.753","upperLimit":"27.112"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.5001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Total Days of Fever","description":"Total days of fever for MVA-NP+M1 vs. Placebo","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"11 days from Day 1 to Day 11","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.6799","statisticalMethod":"zero-inflated poisson model"}]},{"type":"SECONDARY","title":"Average Total Mucus Production","description":"Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo.\n\nTotal mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).","populationDescription":"Total mucus production was only calculated for challenge cohorts 5 to 8 and only if all tissues (cleaned or used) were returned.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"grams","timeFrame":"11 days from Day 1 to Day 11","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.09","lowerLimit":"16.23","upperLimit":"45.85"},{"groupId":"OG001","value":"38.21","lowerLimit":"16.78","upperLimit":"59.63"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.5911","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence","description":"T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay.\n\nFor each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO).\n\nThe number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported.\n\nThe endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Spot-forming units per million","timeFrame":"3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)","groups":[{"id":"OG000","title":"MVA-NP+M1 (ITT)","description":"Intention-to-treat"},{"id":"OG001","title":"Placebo (ITT)","description":"Intention-to-treat"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"title":"Baseline (Vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":"265"},{"groupId":"OG001","value":"167","spread":"157"}]}]},{"title":"Day 8 (from Vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"645","spread":"634"},{"groupId":"OG001","value":"170","spread":"144"}]}]},{"title":"Day 28 (from Vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"566","spread":"551"},{"groupId":"OG001","value":"163","spread":"160"}]}]},{"title":"Day 0 Challenge Period","categories":[{"measurements":[{"groupId":"OG000","value":"460","spread":"471"},{"groupId":"OG001","value":"159","spread":"132"}]}]},{"title":"Day 28 Challenge Period","categories":[{"measurements":[{"groupId":"OG000","value":"561","spread":"483"},{"groupId":"OG001","value":"329","spread":"220"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms","description":"Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries","populationDescription":"Safety Analysis Set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days following vaccination","groups":[{"id":"OG000","title":"MVA-NP+M1","description":"Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)\n\nMVA-NP+M1: Trial Vaccine"},{"id":"OG001","title":"Saline Placebo","description":"Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)\n\nSaline: Sodium Chloride Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"58"}]}],"classes":[{"title":"TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"18"}]}]},{"title":"Solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"24"}]}]},{"title":"TEAE or solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"34"}]}]},{"title":"Local solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"8"}]}]},{"title":"Local Grade 3 solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Systemic solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"20"}]}]},{"title":"Systemic Grade 3 solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"TEAE of special interest","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Non-serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"18"}]}]},{"title":"Grade ≥3 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade ≥3 TE laboratory toxicity","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fatal TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"TEAE related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}]},{"title":"Serious TEAE related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade ≥3 TEAE related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"TEAE for which the study was discontinued","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms","description":"Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"17 days following vaccination","groups":[{"id":"OG000","title":"MVA-NP+M1 (Challenge)","description":"Safety Analysis Set (challenged participants)"},{"id":"OG001","title":"Placebo (Challenge)","description":"Safety Analysis Set (challenged participants)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"47"}]}],"classes":[{"title":"TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"21"}]}]},{"title":"Solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"40"}]}]},{"title":"TEAE or solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"42"}]}]},{"title":"Local solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"39"}]}]},{"title":"Local Grade 3 solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Systemic solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"32"}]}]},{"title":"Systemic Grade 3 solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"TEAE of special interest","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Non-serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"20"}]}]},{"title":"Grade ≥3 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade ≥3 TE laboratory toxicity","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}]},{"title":"Fatal TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"TEAE related to challenge","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}]}]},{"title":"Serious TEAE related to challenge","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade ≥3 TEAE related to challenge","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"TEAE for which the study was discontinued","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Severity of Individual Symptoms for MVA-NP+M1 vs. Placebo","description":"Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo","reportingStatus":"NOT_POSTED","timeFrame":"11 days","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Total Symptom Score Time to Start, Time to Peak and Duration","description":"Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate\n\nInfluenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).","reportingStatus":"NOT_POSTED","timeFrame":"11 days","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Correlation of T Cell Phenotypes With Illness Outcomes","description":"Correlation of antigen specific T Cell phenotypes with illness outcomes","reportingStatus":"NOT_POSTED","timeFrame":"3 months","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Vaccination Effect on Antibody Responses by ELISpot and ICS Assays","description":"Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)","reportingStatus":"NOT_POSTED","timeFrame":"3 months","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Any time during the study from the first administration of any study drug until the last study-related activity (the outpatient visit at 27 days ±3 days following the challenge or 6 months following vaccination ±14 days, whichever is longer)","description":"Treatment-emergent adverse events (TEAE) are defined as the Adverse Events starting during or after first administration of any study drug to the end of the study independently of their intensity and if they are related or not to the study drug.","eventGroups":[{"id":"EG000","title":"MVA-NP+M1 (Vaccination Phase)","description":"Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu.);\n\nMVA-NP+M1: Trial Vaccine","deathsNumAffected":0,"deathsNumAtRisk":87,"seriousNumAffected":1,"seriousNumAtRisk":87,"otherNumAffected":36,"otherNumAtRisk":87},{"id":"EG001","title":"Saline Placebo (Vaccination Phase)","description":"Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%);\n\nSaline: Sodium Chloride Placebo","deathsNumAffected":0,"deathsNumAtRisk":58,"seriousNumAffected":0,"seriousNumAtRisk":58,"otherNumAffected":18,"otherNumAtRisk":58},{"id":"EG002","title":"MVA-NP+M1 (Challenge Phase)","description":"Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu.);\n\nMVA-NP+M1: Trial Vaccine\n\nChallenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)","deathsNumAffected":0,"deathsNumAtRisk":71,"seriousNumAffected":0,"seriousNumAtRisk":71,"otherNumAffected":30,"otherNumAtRisk":71},{"id":"EG003","title":"Saline Placebo (Challenge Phase)","description":"Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%);\n\nSaline: Sodium Chloride Placebo\n\nChallenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\\^6 TCID50/ml)","deathsNumAffected":0,"deathsNumAtRisk":47,"seriousNumAffected":1,"seriousNumAtRisk":47,"otherNumAffected":21,"otherNumAtRisk":47}],"seriousEvents":[{"term":"Foetal death","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Acute Psychosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]}],"otherEvents":[{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":87},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Oral Herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Throat Irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":87},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Dry Throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":87},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Abdominal Discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":47}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Dry Mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Regurgitation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":87},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Dizziness Postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Skin Irritation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Dry Skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":47}]},{"term":"Neck Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Bursitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Flank Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Musculoskeletal Stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Subcutaneous Haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Arthropod Bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Joint Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Ligament Sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Skin Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Lacrimation Increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Swelling of Eyelid","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Eye Irritation","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Conjunctival Hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Ear Discomfort","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Scar Excision","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":47}]},{"term":"Atrial Flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":87},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":47}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Tom Evans, MD","organization":"Vaccitech Ltd.","email":"enquiries@vaccitech.co.uk","phone":"+44 01865 591 445"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-07-10","uploadDate":"2020-12-04T06:12","filename":"Prot_000.pdf","size":2320629},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-06-15","uploadDate":"2020-12-04T06:12","filename":"SAP_001.pdf","size":809552}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2020-12-31","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}